ReVivo Medical

Executive Summary

ReVivo Medical is a private medical device company based in San Diego, developing next-generation spinal implants for anterior cervical discectomy and fusion (ACDF) procedures. Its flagship products, the CEM-Plate and CEM-Cage, are designed to improve patient outcomes and surgical workflow. The company is currently conducting a first-in-human FDA-sanctioned IDE clinical trial to evaluate these devices. With a focus on addressing unmet needs in spinal fusion, ReVivo aims to enhance fusion rates and reduce complications, positioning itself as a potential leader in the regenerative medicine and medical device space. The company's technology leverages advanced materials and design to promote bone growth and stability. The ongoing clinical trial is a critical milestone; successful outcomes could pave the way for FDA clearance and commercialization. ReVivo operates in a competitive market but differentiates through its novel implant design. Given the early stage of clinical development, the company faces regulatory and execution risks. However, its innovative approach and clear clinical pathway support a moderate conviction score. Key upcoming catalysts include trial data readouts, potential regulatory submissions, and strategic partnerships.

Upcoming Catalysts (preview)

• Q1 2027First-in-human IDE trial interim results65% success
• Q4 2027FDA 510(k) clearance or PMA submission55% success
• Q2 2027Strategic partnership or licensing deal for commercialization60% success